Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 1720-1723, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gundberg, C. M.
Right arrow Articles by Parfitt, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gundberg, C. M.
Right arrow Articles by Parfitt, A. M.

Clinical Chemistry, Vol 31, 1720-1723, Copyright © 1985 by American Association for Clinical Chemistry

Determination of osteocalcin in human serum: results with two kits compared with those by a well-characterized assay

CM Gundberg, PS Wilson, PM Gallop and AM Parfitt

Osteocalcin, the vitamin K-dependent protein in bone, can also be detected in serum and is receiving increased attention as a marker for bone turnover in evaluating patients with metabolic bone disease. We compared results for patients as determined with two commercial radioimmunoassay kits (Immuno Nuclear Corp. and Seragen Inc.) and with our in-house radioimmunoassay (Methods Enzymol 107: 517, 1984). Results by our assay correlated well (r greater than 0.9) with those by both kits, but the values by the Immuno Nuclear and Seragen methods were respectively 40% and 10% lower than by our radioimmunoassay. Within-run variation (CV) for the two kit methods was respectively 7.3% and 9.8%, run-to-run CV was 9.7% and 8.6%. The standard curve was linear from 1 to 25 micrograms/L for the Immuno Nuclear kit, from 4 to 100 micrograms/L for the Seragen equilibrium method, and from 1 to 25 micrograms/L for the Seragen nonequilibrium method. A second freeze- thaw cycle reduced the serum values by 20% to 40% for both kit methods. A third freeze-thaw cycle further reduced values and eliminated any correlation among methods.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. Rubin, K. H. Lee, D. J. McMahon, and S. J. Silverberg
Raloxifene Lowers Serum Calcium and Markers of Bone Turnover in Postmenopausal Women with Primary Hyperparathyroidism
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1174 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. S. Kurland, F. Cosman, D. J. McMahon, C. J. Rosen, R. Lindsay, and J. P. Bilezikian
Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3069 - 3076.
[Abstract] [Full Text]

Home page
 NEJMHome page
S. J. Silverberg, E. Shane, T. P. Jacobs, E. Siris, and J. P. Bilezikian
A 10-Year Prospective Study of Primary Hyperparathyroidism with or without Parathyroid Surgery
N. Engl. J. Med., October 21, 1999; 341(17): 1249 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L.-P. BOULET, J. MILOT, L. GAGNON, P. E. POUBELLE, and J. BROWN
Long-Term Influence of Inhaled Corticosteroids on Bone Metabolism and Density . Are Biological Markers Predictors of Bone Loss?
Am. J. Respir. Crit. Care Med., March 1, 1999; 159(3): 838 - 844.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
P. Magnusson, L. Larsson, G. Englund, B. Larsson, P. Strang, and L. Selin-Sjogren
Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain
Clin. Chem., August 1, 1998; 44(8): 1621 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. S. DONOVAN Jr., A. PAPADOPOULOS, R. B. STARON, V. ADDESSO, L. SCHULMAN, C. MCGREGOR, F. COSMAN, R. L. LINDSAY, and E. SHANE
Bone Mass and Vitamin D Deficiency in Adults with Advanced Cystic Fibrosis Lung Disease
Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1892 - 1899.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. S. Kurland, C. J. Rosen, F. Cosman, D. McMahon, F. Chan, E. Shane, R. Lindsay, D. Dempster, and J. P. Bilezikian
Insulin-Like Growth Factor-I in Men with Idiopathic Osteoporosis
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2799 - 2805.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Shane, M. Rivas, D. J. McMahon, R. B. Staron, S. J. Silverberg, M. J. Seibel, D. Mancini, R. E. Michler, K. Aaronson, V. Addesso, et al.
Bone Loss and Turnover after Cardiac Transplantation
J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1497 - 1506.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.